This paper examines the Saudi Arabian pharmaceutical market, the largest in the Gulf Cooperation Council (GCC), accounting for 65% of the region's $1.7 billion pharmaceutical sector. Using PEST and Porter's Five Forces frameworks, the paper explores the market's unique characteristics — including strong consumer preference for brand-name drugs over generics, the absence of prescription requirements, and growing obesity rates — alongside key opportunities such as mandatory health insurance legislation, 100% foreign ownership of manufacturing facilities, and WTO membership. Challenges including strict price controls and import distribution limits are also addressed. The analysis concludes that significant investment potential exists for brand-name pharmaceutical manufacturers in the Kingdom.
The Saudi Arabian pharmaceutical market is one of the largest in the Middle East. Within the Gulf Cooperation Council (GCC), Saudi Arabia represents 65%, or $1.7 billion, of the pharmaceutical market (EPSICOM, 2011). This paper analyzes the unique opportunities within the Saudi pharmaceutical industry along with challenges such as heavily regulated price controls and the barriers to access faced by international pharmaceutical companies. Through a better understanding of these factors, a more complete picture of the market can be obtained.
Saudi Arabia is a unique pharmaceutical market. It is the largest consumer in the GCC, with more than 82% of the medicines utilized being imported (Baines, 2009). The GCC is also distinctive from nearly every other global region in that patients favor brand-name products over generics. This is despite the fact that generics constitute the vast majority of drugs produced in the Kingdom and the GCC. One study estimates the market share of generics in Saudi Arabia at just 5.8%, compared to 50% in many European countries (EPSICOM, 2011).
Another unique aspect of the Saudi pharmaceutical market is that medications can be purchased from a pharmacy without a prescription. This allows consumers to easily act on their brand preferences (Baines, 2009). In short, Saudi Arabia and the broader GCC present extensive and unique characteristics that must be considered in any business decision made in the region.
Most market analysts consider the region to be a tremendous opportunity. Saudi Arabia recently passed legislation requiring medical insurance for all companies operating in the Kingdom with more than fifty international employees. Furthermore, the Kingdom permits manufacturing facilities to be 100% foreign owned and provides various low-cost loan and energy programs to encourage investment (EPSICOM, 2011). As a relatively new member of the World Trade Organization (WTO), Saudi Arabia has also improved its protection of intellectual property and continues to liberalize its economy as it diversifies away from oil. However, obstacles remain, including strict price controls and limits on the distribution of pharmaceutical products produced abroad (Baines, 2009).
Political: Saudi Arabia has a stable government that offers significant political advantages and disadvantages. New legislation is being enacted to provide health insurance, and significant government support exists in the form of loans and energy resources to encourage investment. However, negative government involvement is also present, leading to strict price controls and limits on the distribution of products produced abroad.
Economic: Saudi Arabia is a growing economy with a 3.7% growth rate and significant secured foreign investment in non-pharmaceutical industries. Within the GCC, Saudi Arabia represents 65%, or $1.7 billion, of the pharmaceutical market.
Social: Saudi Arabia has extremely distinctive cultural factors relating to the pharmaceutical industry. Obesity is a growing public health concern, with health officials identifying it as one of the leading causes of preventable deaths in the country. Saudi Arabia ranked 29th on a 2007 list of the world's most overweight nations, with 68.3% of its citizens classified as overweight (BMI > 25). Additionally, Saudi consumers strongly prefer brand-name products over generics, a preference that is highly unusual by global standards.
Technological: Significant government support exists for research and development activity, automation, and technological innovation. The presence of numerous foreign workers also provides important intellectual resources.
Environmental: Environmental factors do not play a significant role in affecting the pharmaceutical industry in Saudi Arabia.
Legal: Though the Kingdom has recently joined the WTO, it remains unclear to what extent the Saudi legal code can be reliably enforced. Protectionist laws regarding imports also present a legal consideration for market entrants.
Threat of New Competition: There exists little risk of new market entrants. As the population of the GCC is generally small, most manufacturers prefer to export to the region rather than establish local production. However, the unique brand loyalty of GCC citizens creates significant market potential for those willing to invest.
"Competitive dynamics and supplier-buyer power"
Baines, E. (2009). Pharmaceuticals: Bringing in the global leaders. Middle East Economic Digest, 53(33).
EPSICOM. (2011). The pharmaceutical market: Saudi Arabia. Retrieved from
You’re 66% through this paper. Sign up to read the remaining 1 section.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.